ValiRx sets up US office, appoints advisory team
UK-based ValiRx (AIM: VAL) on Thursday said it has set up its US operations in Cambridge, Boston, Massachusetts and has also appointed industry specific advisors in the US.
Satu Vainikka, chief executive of ValiRx, said: “ValiRx’s expansion into the US is part of our strategy to strengthen our investor base and to take advantage of close proximity to the biggest biotech market in the world. With VAL201 progressing in the Phase I/II trial and VAL401 on the verge of entering a Phase IIb Clinical Trial, we also felt it important to support our drug development program by strengthening the team, particularly in the US. It is an exciting time for the group and I look forward to benefiting rapidly from our US presence.”
The company said the US operation is being setup to encourage and facilitate greater interaction with academic, clinical and business leaders in ValiRx’s areas of oncological development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze